Universal Beteiligungs und Servicegesellschaft mbH Purchases 5,855 Shares of Rhythm Pharmaceuticals, Inc. $RYTM

Universal Beteiligungs und Servicegesellschaft mbH lifted its position in Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) by 6.1% in the 3rd quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 101,372 shares of the company’s stock after acquiring an additional 5,855 shares during the period. Universal Beteiligungs und Servicegesellschaft mbH owned 0.15% of Rhythm Pharmaceuticals worth $10,238,000 as of its most recent SEC filing.

Other hedge funds also recently made changes to their positions in the company. Farther Finance Advisors LLC raised its holdings in Rhythm Pharmaceuticals by 1,110.3% in the third quarter. Farther Finance Advisors LLC now owns 351 shares of the company’s stock worth $35,000 after purchasing an additional 322 shares in the last quarter. Osaic Holdings Inc. boosted its holdings in shares of Rhythm Pharmaceuticals by 65.9% during the 2nd quarter. Osaic Holdings Inc. now owns 979 shares of the company’s stock valued at $62,000 after buying an additional 389 shares in the last quarter. State of Wyoming purchased a new stake in shares of Rhythm Pharmaceuticals in the 2nd quarter worth about $67,000. Bayforest Capital Ltd increased its stake in shares of Rhythm Pharmaceuticals by 909.5% in the 3rd quarter. Bayforest Capital Ltd now owns 1,171 shares of the company’s stock worth $118,000 after acquiring an additional 1,055 shares in the last quarter. Finally, RWC Asset Management LLP purchased a new position in Rhythm Pharmaceuticals during the 3rd quarter valued at about $201,000.

Insider Buying and Selling at Rhythm Pharmaceuticals

In other Rhythm Pharmaceuticals news, insider Pamela J. Cramer sold 3,350 shares of the company’s stock in a transaction dated Thursday, December 11th. The shares were sold at an average price of $111.00, for a total transaction of $371,850.00. Following the transaction, the insider owned 20,814 shares in the company, valued at approximately $2,310,354. This represents a 13.86% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Joseph Shulman sold 9,748 shares of the firm’s stock in a transaction dated Thursday, October 30th. The shares were sold at an average price of $115.24, for a total transaction of $1,123,359.52. Following the sale, the insider directly owned 8,509 shares in the company, valued at approximately $980,577.16. The trade was a 53.39% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold 15,913 shares of company stock worth $1,818,963 over the last ninety days. 6.10% of the stock is currently owned by insiders.

Rhythm Pharmaceuticals Stock Down 4.8%

Shares of NASDAQ RYTM opened at $103.12 on Friday. Rhythm Pharmaceuticals, Inc. has a twelve month low of $45.90 and a twelve month high of $122.20. The firm has a market cap of $6.88 billion, a P/E ratio of -33.26 and a beta of 2.00. The company has a 50 day moving average of $106.50 and a 200 day moving average of $101.35.

Rhythm Pharmaceuticals (NASDAQ:RYTM) last issued its earnings results on Tuesday, November 4th. The company reported ($0.82) EPS for the quarter, missing the consensus estimate of ($0.72) by ($0.10). The business had revenue of $51.30 million for the quarter, compared to analysts’ expectations of $50.71 million. Rhythm Pharmaceuticals had a negative net margin of 110.32% and a negative return on equity of 433.21%. As a group, equities analysts expect that Rhythm Pharmaceuticals, Inc. will post -4.32 earnings per share for the current fiscal year.

Analysts Set New Price Targets

RYTM has been the topic of a number of recent research reports. HC Wainwright upped their price objective on shares of Rhythm Pharmaceuticals from $123.00 to $125.00 and gave the stock a “buy” rating in a report on Tuesday. Needham & Company LLC boosted their price target on Rhythm Pharmaceuticals from $145.00 to $148.00 and gave the stock a “buy” rating in a research report on Friday, January 9th. TD Cowen restated a “buy” rating on shares of Rhythm Pharmaceuticals in a research note on Thursday, December 11th. Wells Fargo & Company lifted their price objective on Rhythm Pharmaceuticals from $129.00 to $145.00 and gave the company an “overweight” rating in a research note on Tuesday. Finally, Wall Street Zen downgraded Rhythm Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Saturday, November 8th. One analyst has rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating, one has assigned a Hold rating and two have given a Sell rating to the company. According to MarketBeat.com, Rhythm Pharmaceuticals presently has a consensus rating of “Moderate Buy” and a consensus price target of $131.29.

About Rhythm Pharmaceuticals

Rhythm Pharmaceuticals, Inc is a clinical‐stage biotechnology company dedicated to developing targeted therapies for rare genetic diseases of obesity and metabolic dysfunction. The company’s research focuses on the melanocortin‐4 receptor (MC4R) pathway, which plays a central role in regulating appetite, energy expenditure and body weight. Using proprietary peptide technology, Rhythm aims to provide precision treatments to patients with specific genetic variants that disrupt normal weight regulation.

The company’s lead investigational product, setmelanotide, is a selective MC4R agonist designed to restore signaling in patients with deficiencies in genes such as POMC, LEPR and PCSK1.